Skip to content

lopinavir-ritonavir

Interactions

Selected Protease Inhibitors/Rifabutin; Rifapentine

This information is generalized and not intended as specific medical advice. Consult your healthcare professional before taking or discontinuing any drug or commencing any course of treatment.

Medical warning:

Serious. These medicines may interact and cause very harmful effects. Contact your healthcare professional (e.g. doctor or pharmacist) for more information.

How the interaction occurs:

When these two medicines are taken together, your body may not process them properly.

What might happen:

Your blood levels of rifabutin may increase and cause harmful effects. Rifabutin and rifapentine may decrease the levels of some protease inhibitors, which may decrease their effectiveness.

What you should do about this interaction:

Make sure that your healthcare professionals (e.g. doctor or pharmacist) know that you are taking these medicines together. If you experience a persistent sore throat or fever, contact your doctor. The dose of your medicines may need adjusting.Your healthcare professionals may already be aware of this drug interaction and may be monitoring you for it. Do not start, stop, or change the dosage of any medicine before checking with them first.

References:

1.Agenerase (amprenavir) Australian prescribing information. GlaxoSmithKline Australia Pty Ltd. November 24, 2004.

2.Agenerase (amprenavir) summary of product characteristics. GlaxoSmithKline UK January 18, 2005.

3.Agenerase (amprenavir) Capsules US prescribing information. GlaxoSmithKline May, 2005.

4.Reyataz (atazanavir sulfate) Australian product information. Bristol-Myers Squibb Pharmaceuticals January 8, 2004.

5.Reyataz (atazanavir) UK summary of product characteristics. Bristol-Myers Squibb Pharmaceuticals Limited September 8, 2008.

6.Reyataz (atazanavir sulfate) US prescribing information. Bristol-Myers Squibb Company August, 2013.

7.Telzir (fosamprenavir calcium) Australian prescribing information. GlaxoSmithKline Australia Pty Ltd. November 24, 2004.

8.Telzir (fosamprenavir calcium) UK summary of product characteristics. GlaxoSmithKline UK October 18. 2013.

9.Lexiva (fosamprenavir calcium) US prescribing information. GlaxoSmithKline February, 2013.

10.Crixivan (indinavir sulfate) Australian prescribing information. Merck Sharp & Dohme (Australia) Pty Ltd. August 11, 2003.

11.Crixivan (indinavir sulfphate) UK summary of product characteristics. Merck Sharp & Dohme Limited September, 2008.

12.Crixivan (indinavir sulfate) US prescribing information. Merck & Co., Inc. February, 2011.

13.Kaletra (lopinavir/ritonavir) UK summary of product characteristics. Abbott Laboratories, Limited July 11, 2008.

14.Kaletra (lopinavir/ritonavir tablets) US prescribing information. Abbott Laboratories January, 2013.

15.Viracept (nelfinavir mesylate) Australian prescribing information. Roche Products Pty Ltd. October 26, 2000.

16.Viracept (nelfinavir mesylate) US prescribing information. Agouron Pharmaceuticals, Inc. May, 2013.

17.Viracept (nelfinavir mesylate) UK summary of product characteristics. Roche Products Limited August 4, 2008.

18.Kaletra (lopinavir/ritonavir) Australian prescribing information. Abbott Australasia Pty. Ltd. April 1, 2004.

19.Aptivus (tipranavir) US prescribing information. Boehringer Ingelheim Pharmaceuticals, Inc. February, 2012.

20.Polk RE, Brophy DF, Israel DS, Patron R, Sadler BM, Chittick GE, Symonds WT, Lou Y, Kristoff D, Stein DS. Pharmacokinetic Interaction between amprenavir and rifabutin or rifampin in healthy males. Antimicrob Agents Chemother 2001 Feb;45(2):502-8.

21.Prezista (darunavir) UK Summary of product characteristics. Janssen-Cilgat LTD August 8, 2008.

22.Prezista (darunavir) Canadian prescribing information. Jannsen-Ortho June, 2008.

23.Prezista (darunavir) US prescribing information. Tibotec Inc. November, 2013.

24.Boulanger C, Hollender E, Farrell K, Stambaugh JJ, Maasen D, Ashkin D, Symes S, Espinoza LA, Rivero RO, Graham JJ, Peloquin CA. Pharmacokinetic evaluation of rifabutin in combination with lopinavir-ritonavir in patients with HIV infection and active tuberculosis. Clin Infect Dis 2009 Nov 1;49(9):1305-11.

25.Kraft WK, McCrea JB, Winchell GA, Carides A, Lowry R, Woolf EJ, Kusma SE, Deutsch PJ, Greenberg HE, Waldman SA. Indinavir and rifabutin drug interactions in healthy volunteers. J Clin Pharmacol 2004 Mar; 44(3):305-13.

26.Hamzeh FM, Benson C, Gerber J, Currier J, McCrea J, Deutsch P, Ruan P, Wu H, Lee J, Flexner C. Steady-state pharmacokinetic interaction of modified-dose indinavir and rifabutin. Clin Pharmacol Ther 2003 Mar; 73(3):159-69.

27.la Porte CJ, Sabo JP, Elgadi M, Cameron DW. Interaction studies of tipranavir-ritonavir with clarithromycin, fluconazole, and rifabutin in healthy volunteers. Antimicrob Agents Chemother 2009 Jan;53(1):162-73.

28.Invirase (saquinavir mesylate) US prescribing information. Roche Laboratories, Inc. February, 2012.

29.Phansalkar S, Desai AA, Bell D, Yoshida E, Doole J, Czochanski M, Middleton B, Bates DW. High-priority drug-drug interactions for use in electronic health records. J Am Med Inform Assoc 2012 Sep-Oct; 19(5):735-43.

Selected from data included with permission and copyrighted by First Databank, Inc. This copyrighted material has been downloaded from a licensed data provider and is not for distribution, expect as may be authorized by the applicable terms of use.

CONDITIONS OF USE: The information in this database is intended to supplement, not substitute for, the expertise and judgment of healthcare professionals. The information is not intended to cover all possible uses, directions, precautions, drug interactions or adverse effects, nor should it be construed to indicate that use of a particular drug is safe, appropriate or effective for you or anyone else. A healthcare professional should be consulted before taking any drug, changing any diet or commencing or discontinuing any course of treatment.

More about Drugs and Medications

Newsletters

Subscribe to free WebMD newsletters.

  • WebMD Daily

    WebMD Daily

    Subscribe to the WebMD Daily, and you'll get today's top health news and trending topics, and the latest and best information from WebMD.

  • Men's Health

    Men's Health

    Subscribe to the Men's Health newsletter for the latest on disease prevention, fitness, sex, nutrition, and more from WebMD.

  • Women's Health

    Women's Health

    Subscribe to the Women's Health newsletter for the latest on disease prevention, fitness, sex, diet, anti-aging, and more from WebMD.

By clicking Submit, I agree to the WebMD Terms & Conditions & Privacy Policy

URAC: Accredited Health Web Site TRUSTe online privacy certification HONcode Seal AdChoices